In 2023, Neil F. McFarlane earned $1.71M in total compensation at Zevra Therapeutics, Inc., including $157.50K salary, $200.00K bonus and $1.31M in stock. 2+ years at the helm of Zevra Therapeutics, Inc..
Compensation History
Annual executive compensation data for Neil F. McFarlane, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$1.71M
Salary
$157.50K
Bonus
$200.00K
Other
$40.74K
Salary
$157.50KBoard Justification
The compensation philosophy is designed to attract, retain, and motivate talented executives, aligning their interests with those of stockholders through performance-based incentives.
Bonus
$200.00KBoard Justification
The bonus is based on the achievement of specified corporate performance objectives, pro-rated for the partial year of employment.
Other Compensation
$40.74KBoard Justification
Includes 401(k) employer matching contributions, travel reimbursements, gross-up tax payments, and legal fee reimbursements related to his employment agreement.
Restricted Stock
Board Justification
The RSUs granted to Mr. McFarlane vest in four equal annual installments, beginning on the first anniversary of his start date, subject to continuous service.
Performance Metrics
Performance metrics include the achievement of specified development, regulatory, and financial milestones.
Neil F. McFarlane
CEO of Zevra Therapeutics, Inc.
Education
B.S. and M.S. degrees in Nursing from the University of Florida
Sector of Economy
Healthcare
Born
January 1, 1972 - 53 years ago
CEO of Zevra Therapeutics, Inc. for
2 years 2 months (Oct 2023 - Present)
Previous Experience
Chief Executive Officer of Adamas Pharmaceuticals, Inc.
Other Zevra Therapeutics, Inc. CEOs
Holdings
Track Neil F. McFarlane's stock holdings and portfolio value over time.
Insider Trading
Neil F. McFarlane's recent stock transactions, purchases, and sales filed with the SEC.
No insider trades found for this CEO.
Rivals
Compare Neil F. McFarlane with competitor CEOs and industry peers.